


Journal of Poultry Sciences and Avian Diseases

Journal homepage: www.jpsad.com



Antimicrobial peptides, their significance and challenges in veterinary medicine



Mohammad Hadi Sekhavati^{1*} 

¹ Department of Animal Science, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran

* Corresponding author email address: sekhavati@um.ac.ir

Article Info

Article type:

Letter to Editor

How to cite this article:

Sekhavati, M. H. (2024). Antimicrobial peptides, their significance and challenges in veterinary medicine. *Journal of Poultry Sciences and Avian Diseases*, 2(4), 54-55.

<http://dx.doi.org/10.61838/kman.jpsad.2.4.8>



© 2024 the authors. Published by SANA AVIAN HOSPITAL, Tehran, Iran. This is an open access article under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) License.

Dear Editor,
 Today, many developed countries have banned the use of antibiotics in the farm animal industry due to the problem of antibiotic resistance and its consequences on human health (1). This limitation has encouraged scientists to introduce safe and effective alternatives to antibiotics. Among these candidates, antimicrobial peptides (AMPs), due to their broad spectrum activities against a wide range of pathogens, their immune-modulatory activities, and the inability of pathogens to resist them, are attractive to scientists (2). AMPs are short-chain peptides with a length of 10 to 50 amino acids with a positive charge, amphipathic properties, and unique tertiary structures. They are the first protective barrier in the animal's innate immune system (3). Many studies have shown that AMPs have antibacterial,

antiviral, antifungal, and antiparasitic properties and anticancer and immune modulatory effects *in vitro* and *in vivo* (3).

The mechanisms of action proposed by AMPs consist of i) binding to the cell membrane and destroying it, ii) binding to specific receptors on the cell surface and preventing pathogens from binding and then entering into the cell, iii) entering the cell and binding to intracellular proteins, DNA and RNA and disturbance in cellular biological processes (3).

Today, computer-based tools such as protein modeling, molecular docking, and molecular dynamic (MD) simulation, as well as artificial intelligence (AI) algorithms, allow for the obtaining of engineered peptides with the best possible functions for therapeutic, agricultural, and veterinary medicine (4).

Article history:

Received 04 April 2024

Revised 25 August 2024

Accepted 01 September 2024

Published online 01 October 2024

Despite all the advantages of AMPs, we still face significant challenges in producing and industrializing these biological compounds in veterinary medicine and feed production (5). Two significant challenges in this field are 1) the cost-effective production of AMPs and 2) the short half-life of AMPs in the bodies of farm animals.

The chemical production of AMPs could be more economical due to the high cost of production. On the other hand, the small size of AMPs and their susceptibility to digestive enzymes cause dramatic drops in the half-life of AMPs in the animal blood circulation and gastrointestinal tract. Today, recombinant DNA technology helps scientists to offset significantly the cost of AMP industrial production. However, there are still difficulties due to the lethal effects of AMPs on the expression host and the low yield of peptide production (6).

According to our findings, yeast is one of the best hosts for producing AMPs (the data was not published). Researchers have also provided other solutions to reduce the cost of AMPs

, such as using the synergistic effects of peptides with antibiotics (7).

Computer-based tools, especially AI, can be suitable for predicting and engineering improved AMPs to increase their half-life. Moreover, using protective carriers for AMPs in the blood circulation and digestive system can protect AMPs from the risk of digestion by enzymes and increase their half-life (8). Some researchers use probiotics as live carriers in the digestive tract to produce AMPs. They generated bioengineered probiotics that can produce and secrete an AMP in the digestive tract (9).

At the end of this letter, it can be summarized that AMPs can be a worthy and attractive alternative to antibiotics. However, there is still a long way to go in using AMPs on a large and industrial scale in the treatment and nutrition of farm animals. Undoubtedly, future research in this field can solve these problems and achieve this important goal.

Acknowledgements

None.

Conflict of Interest

The author has no conflict of interest to declare.

Author Contributions

Not applicable.

Data Availability Statement

Not applicable.

Ethical Considerations

Not applicable.

Funding

No funding was received to assist with the preparation of this manuscript.

References

1. Manyi-Loh C, Mamphweli S, Meyer E, Okoh A. Antibiotic use in agriculture and its consequential resistance in environmental sources: potential public health implications. *Molecules*. 2018;23(4):795. [PMID: 29601469] [PMCID: PMC6017557] [DOI]
2. Silveira RF, Roque-Borda CA, Vicente EF. Antimicrobial peptides as a feed additive alternative to animal production, food safety and public health implications: An overview. *Animal Nutrition*. 2021;7(3):896-904. [PMID: 34632120] [PMCID: PMC8484980] [DOI]
3. Huan Y, Kong Q, Mou H, Yi H. Antimicrobial peptides: classification, design, application and research progress in multiple fields. *Frontiers in microbiology*. 2020;11:582779. [PMID: 33178164] [PMCID: PMC7596191] [DOI]
4. Maccari G, Di Luca M, Nifosi R. In silico design of antimicrobial peptides. *Computational Peptidology*. 2015:195-219. [PMID: 25555726] [DOI]
5. de Oliveira KBS, Leite ML, Cunha VA, da Cunha NB, Franco OL. Challenges and advances in antimicrobial peptide development. *Drug Discovery Today*. 2023:103629. [PMID: 37230283] [DOI]
6. Tanhaiean A, Azghandi M, Razmyar J, Mohammadi E, Sekhavati MH. Recombinant production of a chimeric antimicrobial peptide in *E. coli* and assessment of its activity against some avian clinically isolated pathogens. *Microbial pathogenesis*. 2018;122:73-8. [PMID: 29890331] [DOI]
7. Roshanak S, Shahidi F, Soradeghi Toopkanloo A, Pirkhezranian Z, Sekhavati MH. Evaluation of antibacterial activity of cLFchimera and its synergistic potential with vancomycin against methicillin-resistant *Staphylococcus aureus*. *Iranian Journal of Veterinary Science and Technology*. 2022;14(1):1-8.
8. Pikkemaat MG, Linssen AB, Berendsen HJ, Janssen DB. Molecular dynamics simulations as a tool for improving protein stability. *Protein engineering*. 2002;15(3):185-92. [PMID: 11932489] [DOI]
9. Tanhaiean A, Mirzaei M, Pirkhezranian Z, Sekhavati MH. Generation of an engineered food-grade *Lactococcus lactis* strain for production of an antimicrobial peptide: in vitro and in silico evaluation. *BMC biotechnology*. 2020;20:1-13. [PMID: 32228563] [PMCID: PMC7106598] [DOI]